nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—Dactinomycin—testicular cancer	0.23	0.284	CbGbCtD
Fidaxomicin—ABCB1—Vinblastine—testicular cancer	0.144	0.178	CbGbCtD
Fidaxomicin—ABCB1—Cisplatin—testicular cancer	0.132	0.163	CbGbCtD
Fidaxomicin—ABCB1—Etoposide—testicular cancer	0.13	0.16	CbGbCtD
Fidaxomicin—ABCB1—Doxorubicin—testicular cancer	0.0887	0.109	CbGbCtD
Fidaxomicin—ABCB1—Methotrexate—testicular cancer	0.0859	0.106	CbGbCtD
Fidaxomicin—Megacolon—Methotrexate—testicular cancer	0.0095	0.0505	CcSEcCtD
Fidaxomicin—Metabolic acidosis—Ifosfamide—testicular cancer	0.00834	0.0443	CcSEcCtD
Fidaxomicin—Metabolic acidosis—Etoposide—testicular cancer	0.00659	0.035	CcSEcCtD
Fidaxomicin—Neutropenia—Chlorambucil—testicular cancer	0.00292	0.0155	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Ifosfamide—testicular cancer	0.00239	0.0127	CcSEcCtD
Fidaxomicin—Dysphagia—Dactinomycin—testicular cancer	0.00226	0.012	CcSEcCtD
Fidaxomicin—Neutropenia—Dactinomycin—testicular cancer	0.00211	0.0112	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Cisplatin—testicular cancer	0.00206	0.011	CcSEcCtD
Fidaxomicin—Anaemia—Chlorambucil—testicular cancer	0.00201	0.0107	CcSEcCtD
Fidaxomicin—Angioedema—Chlorambucil—testicular cancer	0.00199	0.0106	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Ifosfamide—testicular cancer	0.00187	0.00992	CcSEcCtD
Fidaxomicin—Anaemia—Vinblastine—testicular cancer	0.00185	0.00981	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00174	0.00927	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00167	0.00886	CcSEcCtD
Fidaxomicin—Dysphagia—Etoposide—testicular cancer	0.00163	0.00868	CcSEcCtD
Fidaxomicin—Dyspepsia—Chlorambucil—testicular cancer	0.00157	0.00832	CcSEcCtD
Fidaxomicin—Anaemia—Bleomycin—testicular cancer	0.00156	0.00829	CcSEcCtD
Fidaxomicin—Decreased appetite—Chlorambucil—testicular cancer	0.00155	0.00822	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00154	0.00816	CcSEcCtD
Fidaxomicin—Neutropenia—Etoposide—testicular cancer	0.00153	0.00812	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Cisplatin—testicular cancer	0.0015	0.00799	CcSEcCtD
Fidaxomicin—Immune system disorder—Ifosfamide—testicular cancer	0.0015	0.00795	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00145	0.00773	CcSEcCtD
Fidaxomicin—Anaemia—Dactinomycin—testicular cancer	0.00145	0.00773	CcSEcCtD
Fidaxomicin—Malnutrition—Ifosfamide—testicular cancer	0.00144	0.00766	CcSEcCtD
Fidaxomicin—Decreased appetite—Vinblastine—testicular cancer	0.00142	0.00753	CcSEcCtD
Fidaxomicin—Abdominal pain—Chlorambucil—testicular cancer	0.00141	0.00747	CcSEcCtD
Fidaxomicin—Constipation—Vinblastine—testicular cancer	0.00139	0.00741	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Etoposide—testicular cancer	0.00138	0.00732	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vinblastine—testicular cancer	0.00133	0.00708	CcSEcCtD
Fidaxomicin—Anaemia—Ifosfamide—testicular cancer	0.00133	0.00708	CcSEcCtD
Fidaxomicin—Angioedema—Ifosfamide—testicular cancer	0.00132	0.007	CcSEcCtD
Fidaxomicin—Hypersensitivity—Chlorambucil—testicular cancer	0.00131	0.00697	CcSEcCtD
Fidaxomicin—Immune system disorder—Cisplatin—testicular cancer	0.00129	0.00685	CcSEcCtD
Fidaxomicin—Abdominal pain—Vinblastine—testicular cancer	0.00129	0.00685	CcSEcCtD
Fidaxomicin—Pruritus—Chlorambucil—testicular cancer	0.00126	0.00669	CcSEcCtD
Fidaxomicin—Malnutrition—Cisplatin—testicular cancer	0.00124	0.00661	CcSEcCtD
Fidaxomicin—Dyspnoea—Bleomycin—testicular cancer	0.00123	0.00652	CcSEcCtD
Fidaxomicin—Flatulence—Cisplatin—testicular cancer	0.00122	0.00651	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00122	0.00648	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vinblastine—testicular cancer	0.0012	0.00638	CcSEcCtD
Fidaxomicin—Decreased appetite—Bleomycin—testicular cancer	0.0012	0.00636	CcSEcCtD
Fidaxomicin—Immune system disorder—Etoposide—testicular cancer	0.00118	0.00628	CcSEcCtD
Fidaxomicin—Nervous system disorder—Ifosfamide—testicular cancer	0.00115	0.00613	CcSEcCtD
Fidaxomicin—Anaemia—Cisplatin—testicular cancer	0.00115	0.00611	CcSEcCtD
Fidaxomicin—Skin disorder—Ifosfamide—testicular cancer	0.00114	0.00607	CcSEcCtD
Fidaxomicin—Vomiting—Chlorambucil—testicular cancer	0.00113	0.00601	CcSEcCtD
Fidaxomicin—Decreased appetite—Dactinomycin—testicular cancer	0.00112	0.00593	CcSEcCtD
Fidaxomicin—Dysgeusia—Etoposide—testicular cancer	0.00111	0.00593	CcSEcCtD
Fidaxomicin—Dizziness—Vinblastine—testicular cancer	0.00108	0.00573	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.00106	0.00563	CcSEcCtD
Fidaxomicin—Nausea—Chlorambucil—testicular cancer	0.00106	0.00562	CcSEcCtD
Fidaxomicin—Anaemia—Etoposide—testicular cancer	0.00105	0.00559	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00105	0.00558	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00105	0.00558	CcSEcCtD
Fidaxomicin—Dyspnoea—Ifosfamide—testicular cancer	0.00105	0.00558	CcSEcCtD
Fidaxomicin—Vomiting—Vinblastine—testicular cancer	0.00104	0.00551	CcSEcCtD
Fidaxomicin—Decreased appetite—Ifosfamide—testicular cancer	0.00102	0.00544	CcSEcCtD
Fidaxomicin—Headache—Vinblastine—testicular cancer	0.00102	0.00543	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00102	0.0054	CcSEcCtD
Fidaxomicin—Abdominal pain—Dactinomycin—testicular cancer	0.00101	0.00539	CcSEcCtD
Fidaxomicin—Hypersensitivity—Bleomycin—testicular cancer	0.00101	0.00539	CcSEcCtD
Fidaxomicin—Constipation—Ifosfamide—testicular cancer	0.00101	0.00535	CcSEcCtD
Fidaxomicin—Nervous system disorder—Cisplatin—testicular cancer	0.000994	0.00529	CcSEcCtD
Fidaxomicin—Skin disorder—Cisplatin—testicular cancer	0.000985	0.00524	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.00098	0.00521	CcSEcCtD
Fidaxomicin—Pruritus—Bleomycin—testicular cancer	0.000974	0.00518	CcSEcCtD
Fidaxomicin—Nausea—Vinblastine—testicular cancer	0.000968	0.00515	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000962	0.00512	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000962	0.00511	CcSEcCtD
Fidaxomicin—Hypersensitivity—Dactinomycin—testicular cancer	0.000946	0.00503	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000934	0.00497	CcSEcCtD
Fidaxomicin—Abdominal pain—Ifosfamide—testicular cancer	0.00093	0.00494	CcSEcCtD
Fidaxomicin—Abdominal distension—Epirubicin—testicular cancer	0.000922	0.0049	CcSEcCtD
Fidaxomicin—Dysphagia—Epirubicin—testicular cancer	0.000916	0.00487	CcSEcCtD
Fidaxomicin—Neutropenia—Methotrexate—testicular cancer	0.000915	0.00486	CcSEcCtD
Fidaxomicin—Dyspnoea—Cisplatin—testicular cancer	0.000904	0.00481	CcSEcCtD
Fidaxomicin—Skin disorder—Etoposide—testicular cancer	0.000902	0.0048	CcSEcCtD
Fidaxomicin—Decreased appetite—Cisplatin—testicular cancer	0.000881	0.00469	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000875	0.00465	CcSEcCtD
Fidaxomicin—Vomiting—Bleomycin—testicular cancer	0.000875	0.00465	CcSEcCtD
Fidaxomicin—Rash—Bleomycin—testicular cancer	0.000868	0.00461	CcSEcCtD
Fidaxomicin—Dermatitis—Bleomycin—testicular cancer	0.000867	0.00461	CcSEcCtD
Fidaxomicin—Hypersensitivity—Ifosfamide—testicular cancer	0.000867	0.00461	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000865	0.0046	CcSEcCtD
Fidaxomicin—Neutropenia—Epirubicin—testicular cancer	0.000856	0.00455	CcSEcCtD
Fidaxomicin—Abdominal distension—Doxorubicin—testicular cancer	0.000853	0.00453	CcSEcCtD
Fidaxomicin—Dysphagia—Doxorubicin—testicular cancer	0.000847	0.0045	CcSEcCtD
Fidaxomicin—Pruritus—Ifosfamide—testicular cancer	0.000832	0.00442	CcSEcCtD
Fidaxomicin—Dyspnoea—Etoposide—testicular cancer	0.000828	0.0044	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Epirubicin—testicular cancer	0.000826	0.00439	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Methotrexate—testicular cancer	0.000825	0.00439	CcSEcCtD
Fidaxomicin—Nausea—Bleomycin—testicular cancer	0.000817	0.00435	CcSEcCtD
Fidaxomicin—Vomiting—Dactinomycin—testicular cancer	0.000816	0.00434	CcSEcCtD
Fidaxomicin—Rash—Dactinomycin—testicular cancer	0.000809	0.0043	CcSEcCtD
Fidaxomicin—Decreased appetite—Etoposide—testicular cancer	0.000808	0.00429	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000802	0.00426	CcSEcCtD
Fidaxomicin—Constipation—Etoposide—testicular cancer	0.000794	0.00422	CcSEcCtD
Fidaxomicin—Neutropenia—Doxorubicin—testicular cancer	0.000792	0.00421	CcSEcCtD
Fidaxomicin—Dizziness—Ifosfamide—testicular cancer	0.000778	0.00414	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Epirubicin—testicular cancer	0.000772	0.00411	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Doxorubicin—testicular cancer	0.000764	0.00406	CcSEcCtD
Fidaxomicin—Nausea—Dactinomycin—testicular cancer	0.000762	0.00405	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Etoposide—testicular cancer	0.00076	0.00404	CcSEcCtD
Fidaxomicin—Vomiting—Ifosfamide—testicular cancer	0.000748	0.00398	CcSEcCtD
Fidaxomicin—Hypersensitivity—Cisplatin—testicular cancer	0.000747	0.00397	CcSEcCtD
Fidaxomicin—Rash—Ifosfamide—testicular cancer	0.000742	0.00394	CcSEcCtD
Fidaxomicin—Dermatitis—Ifosfamide—testicular cancer	0.000741	0.00394	CcSEcCtD
Fidaxomicin—Abdominal pain—Etoposide—testicular cancer	0.000734	0.0039	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000714	0.0038	CcSEcCtD
Fidaxomicin—Immune system disorder—Methotrexate—testicular cancer	0.000707	0.00376	CcSEcCtD
Fidaxomicin—Nausea—Ifosfamide—testicular cancer	0.000699	0.00371	CcSEcCtD
Fidaxomicin—Hypersensitivity—Etoposide—testicular cancer	0.000684	0.00364	CcSEcCtD
Fidaxomicin—Malnutrition—Methotrexate—testicular cancer	0.000682	0.00362	CcSEcCtD
Fidaxomicin—Dysgeusia—Methotrexate—testicular cancer	0.000668	0.00355	CcSEcCtD
Fidaxomicin—Immune system disorder—Epirubicin—testicular cancer	0.000662	0.00352	CcSEcCtD
Fidaxomicin—Pruritus—Etoposide—testicular cancer	0.000657	0.00349	CcSEcCtD
Fidaxomicin—Vomiting—Cisplatin—testicular cancer	0.000645	0.00343	CcSEcCtD
Fidaxomicin—Rash—Cisplatin—testicular cancer	0.000639	0.0034	CcSEcCtD
Fidaxomicin—Dermatitis—Cisplatin—testicular cancer	0.000639	0.0034	CcSEcCtD
Fidaxomicin—Malnutrition—Epirubicin—testicular cancer	0.000638	0.00339	CcSEcCtD
Fidaxomicin—Anaemia—Methotrexate—testicular cancer	0.00063	0.00335	CcSEcCtD
Fidaxomicin—Flatulence—Epirubicin—testicular cancer	0.000629	0.00334	CcSEcCtD
Fidaxomicin—Dysgeusia—Epirubicin—testicular cancer	0.000625	0.00332	CcSEcCtD
Fidaxomicin—Dizziness—Etoposide—testicular cancer	0.000614	0.00327	CcSEcCtD
Fidaxomicin—Immune system disorder—Doxorubicin—testicular cancer	0.000613	0.00326	CcSEcCtD
Fidaxomicin—Nausea—Cisplatin—testicular cancer	0.000602	0.0032	CcSEcCtD
Fidaxomicin—Vomiting—Etoposide—testicular cancer	0.000591	0.00314	CcSEcCtD
Fidaxomicin—Malnutrition—Doxorubicin—testicular cancer	0.00059	0.00314	CcSEcCtD
Fidaxomicin—Anaemia—Epirubicin—testicular cancer	0.00059	0.00314	CcSEcCtD
Fidaxomicin—Rash—Etoposide—testicular cancer	0.000586	0.00311	CcSEcCtD
Fidaxomicin—Dermatitis—Etoposide—testicular cancer	0.000585	0.00311	CcSEcCtD
Fidaxomicin—Headache—Etoposide—testicular cancer	0.000582	0.00309	CcSEcCtD
Fidaxomicin—Flatulence—Doxorubicin—testicular cancer	0.000582	0.00309	CcSEcCtD
Fidaxomicin—Dysgeusia—Doxorubicin—testicular cancer	0.000578	0.00307	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000576	0.00306	CcSEcCtD
Fidaxomicin—Nausea—Etoposide—testicular cancer	0.000552	0.00293	CcSEcCtD
Fidaxomicin—Nervous system disorder—Methotrexate—testicular cancer	0.000546	0.0029	CcSEcCtD
Fidaxomicin—Anaemia—Doxorubicin—testicular cancer	0.000546	0.0029	CcSEcCtD
Fidaxomicin—Skin disorder—Methotrexate—testicular cancer	0.00054	0.00287	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000539	0.00287	CcSEcCtD
Fidaxomicin—Dry mouth—Epirubicin—testicular cancer	0.000531	0.00282	CcSEcCtD
Fidaxomicin—Nervous system disorder—Epirubicin—testicular cancer	0.000511	0.00271	CcSEcCtD
Fidaxomicin—Skin disorder—Epirubicin—testicular cancer	0.000506	0.00269	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000499	0.00265	CcSEcCtD
Fidaxomicin—Dyspnoea—Methotrexate—testicular cancer	0.000496	0.00264	CcSEcCtD
Fidaxomicin—Dry mouth—Doxorubicin—testicular cancer	0.000492	0.00261	CcSEcCtD
Fidaxomicin—Dyspepsia—Methotrexate—testicular cancer	0.00049	0.0026	CcSEcCtD
Fidaxomicin—Decreased appetite—Methotrexate—testicular cancer	0.000484	0.00257	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00048	0.00255	CcSEcCtD
Fidaxomicin—Nervous system disorder—Doxorubicin—testicular cancer	0.000473	0.00251	CcSEcCtD
Fidaxomicin—Skin disorder—Doxorubicin—testicular cancer	0.000468	0.00249	CcSEcCtD
Fidaxomicin—Dyspnoea—Epirubicin—testicular cancer	0.000464	0.00247	CcSEcCtD
Fidaxomicin—Dyspepsia—Epirubicin—testicular cancer	0.000458	0.00244	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Methotrexate—testicular cancer	0.000455	0.00242	CcSEcCtD
Fidaxomicin—Decreased appetite—Epirubicin—testicular cancer	0.000453	0.00241	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00045	0.00239	CcSEcCtD
Fidaxomicin—Constipation—Epirubicin—testicular cancer	0.000445	0.00237	CcSEcCtD
Fidaxomicin—Abdominal pain—Methotrexate—testicular cancer	0.00044	0.00234	CcSEcCtD
Fidaxomicin—Dyspnoea—Doxorubicin—testicular cancer	0.00043	0.00228	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000426	0.00226	CcSEcCtD
Fidaxomicin—Dyspepsia—Doxorubicin—testicular cancer	0.000424	0.00225	CcSEcCtD
Fidaxomicin—Decreased appetite—Doxorubicin—testicular cancer	0.000419	0.00223	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000416	0.00221	CcSEcCtD
Fidaxomicin—Constipation—Doxorubicin—testicular cancer	0.000412	0.00219	CcSEcCtD
Fidaxomicin—Abdominal pain—Epirubicin—testicular cancer	0.000412	0.00219	CcSEcCtD
Fidaxomicin—Hypersensitivity—Methotrexate—testicular cancer	0.00041	0.00218	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000394	0.00209	CcSEcCtD
Fidaxomicin—Pruritus—Methotrexate—testicular cancer	0.000394	0.00209	CcSEcCtD
Fidaxomicin—Hypersensitivity—Epirubicin—testicular cancer	0.000384	0.00204	CcSEcCtD
Fidaxomicin—Abdominal pain—Doxorubicin—testicular cancer	0.000381	0.00202	CcSEcCtD
Fidaxomicin—Pruritus—Epirubicin—testicular cancer	0.000368	0.00196	CcSEcCtD
Fidaxomicin—Dizziness—Methotrexate—testicular cancer	0.000368	0.00196	CcSEcCtD
Fidaxomicin—Hypersensitivity—Doxorubicin—testicular cancer	0.000355	0.00189	CcSEcCtD
Fidaxomicin—Vomiting—Methotrexate—testicular cancer	0.000354	0.00188	CcSEcCtD
Fidaxomicin—Rash—Methotrexate—testicular cancer	0.000351	0.00187	CcSEcCtD
Fidaxomicin—Dermatitis—Methotrexate—testicular cancer	0.000351	0.00186	CcSEcCtD
Fidaxomicin—Headache—Methotrexate—testicular cancer	0.000349	0.00185	CcSEcCtD
Fidaxomicin—Dizziness—Epirubicin—testicular cancer	0.000344	0.00183	CcSEcCtD
Fidaxomicin—Pruritus—Doxorubicin—testicular cancer	0.000341	0.00181	CcSEcCtD
Fidaxomicin—Vomiting—Epirubicin—testicular cancer	0.000331	0.00176	CcSEcCtD
Fidaxomicin—Nausea—Methotrexate—testicular cancer	0.000331	0.00176	CcSEcCtD
Fidaxomicin—Rash—Epirubicin—testicular cancer	0.000328	0.00175	CcSEcCtD
Fidaxomicin—Dermatitis—Epirubicin—testicular cancer	0.000328	0.00174	CcSEcCtD
Fidaxomicin—Headache—Epirubicin—testicular cancer	0.000326	0.00173	CcSEcCtD
Fidaxomicin—Dizziness—Doxorubicin—testicular cancer	0.000319	0.00169	CcSEcCtD
Fidaxomicin—Nausea—Epirubicin—testicular cancer	0.000309	0.00164	CcSEcCtD
Fidaxomicin—Vomiting—Doxorubicin—testicular cancer	0.000306	0.00163	CcSEcCtD
Fidaxomicin—Rash—Doxorubicin—testicular cancer	0.000304	0.00162	CcSEcCtD
Fidaxomicin—Dermatitis—Doxorubicin—testicular cancer	0.000304	0.00161	CcSEcCtD
Fidaxomicin—Headache—Doxorubicin—testicular cancer	0.000302	0.0016	CcSEcCtD
Fidaxomicin—Nausea—Doxorubicin—testicular cancer	0.000286	0.00152	CcSEcCtD
